Skip to main content
SpringerLink
Log in

Biogen Idec and Elan have announced four new cases of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri (natalizumab),

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Biogen Idec Inc.Biogen, Elan's Drug Linked to 35 Brain-Disease Cases (Update1). Media Release: 16 Feb 2010. Available from: URL: http://www.biogenidec.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Biogen Idec and Elan have announced four new cases of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri (natalizumab),. React. Wkly. 1290, 3 (2010). https://doi.org/10.2165/00128415-201012900-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201012900-00007

Keywords

Search

Navigation